<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446260</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1811-I-101</org_study_id>
    <nct_id>NCT04446260</nct_id>
  </id_info>
  <brief_title>A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics
      and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or
      mutated advanced malignant solid tumor subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>From Day1 to 90 days after last dose</time_frame>
    <description>Frequency and seriousness of treatment emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Tmax of SHR-A1811</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Time to maximal concentration (Tmax) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Cmax of SHR-A1811</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Maximal concentration (Cmax) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC0-t of SHR-A1811</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>AUC computed from time zero to the time of the last quantifiable concentration (AUC0-t) of SHR-A1811</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SHR-A1811</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Including anti-drug antibody and/or neutralizing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response using RECIST 1.1</measure>
    <time_frame>From first dose to disease progression or death, whichever comes first, up to 30 months</time_frame>
    <description>RECIST=Response Evaluation Criteria in Solid Tumors Assessment of tumor response until disease progression or death to evaluate the efficacy of SHR-A1811 up to 30 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Indication expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811</intervention_name>
    <description>be administered via intravenous (IV) infusion</description>
    <arm_group_label>Part 1 Dose escalation</arm_group_label>
    <arm_group_label>Part 2 Indication expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced/unresectable or metastatic solid tumor with HER2 expression or mutation that
             is refractory to or intolerable with standard treatment, or for which no standard
             treatment is available

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  LVEF â‰¥ 50% by either ECHO or MUGA

          -  Has adequate renal and hepatic function

          -  Female subjects agree not to be pregnant or lactating from beginning of the study
             screening until 6 months after receiving the last treatment

        Exclusion Criteria:

          -  History of clinically significant lung diseases (e.g., interstitial pneumonia,
             pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected to
             have these diseases by imaging at screening period

          -  Known hereditary or acquired bleeding and thrombotic tendency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sherry Zhu, MD, PhD</last_name>
    <phone>+86 021-61053363</phone>
    <email>zhuxiaoyu@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Rong</last_name>
    <phone>+86 021-61053363</phone>
    <email>rongshangyi@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

